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A group of Merck scientists in the United States and Spain have now come up with a very clever screening
technique and discovered an unique antibiotic (Phillips et al., 2011). Such discoveries are sorely needed to
assist us out of the antibiotic crisis that the world is now experiencing.Theworld is in dire need of new antibiotics
(Spı´zek et al., 2010). It is encouraging that
a new class of antibiotics, represented by
kibdelomycin, is still being discovered in
the face of the antibiotic crisis that exists
today globally. Infectious disease is the
second most important killer of humans
in the world. About 17 million people die
each year as a result of bacterial infec-
tions (Butler and Buss, 2006). Not only
are we battling the increase in antibiotic
resistance in known pathogens, but there
are at least 30 new bacterial and viral
diseases that have emerged since the
1980s. However, despite this, most of
the international pharmaceutical industry
is moving away from antibiotic discovery
(Demain, 2002). Large pharmaceutical
companies that have dropped or signifi-
cantly reduced research on antibiotic
discovery include Merck, Wyeth (now
part of Pfizer), Aventis, Eli Lilly, Abbott
Laboratories, Bristol-Myers Squibb, and
Schering-Plough (now part of Merck)
(Barrett, 2005). This is easily seen by the
drop in the number of approvals of new
antibiotics by the regulatory agencies.
New antimicrobial approvals, which were
commercialized between 1983 and
1987, amounted to 16. In the period of
2003-2007, this had dropped to five, and
the numbers from 2008 to 2010 were
down to two. Much of this is caused by
the increased difficulty in isolating novel
drugs, including antibiotics. Factors that
have affected the discovery of all drugs
include ‘‘merger mania’’ in the industry,
the increased development time and
cost for clinical trials, the shift away from
natural product discovery in favor of com-
binatorial chemistry, genomics and pro-teomics, and the decreases in research
and development spending by the in-
dustry since 2001, due to the movement
of industry funds from research to the
promotion of already known drugs. For
instance, in 1991, the amount spent by
the pharmaceutical industry to market,
promote, and advertise their products
was 9.2 billion dollars. By 2004, this
amount had increased to 25 billion
dollars, mainly due to direct advertising
to consumers, free drug samples, and
salaries for drug representatives.
In this issue, a novel screening tech-
nique is described thatwas usedby scien-
tists at Merck & Co. in the United States
and Spain to come up with an exciting
new antibiotic called kibdelomycin (Phil-
lips et al., 2011). This novel compound,
produced by Kibdelosporangium sp, is
a potent inhibitor of bacterial type-II topo-
isomerases, preferentially inhibiting the
ATPase activity of DNA gyrase and topo-
isomerase IV. As a result, it has broad-
spectrum activity against Gram-positive
bacteria such as Staphylococcus aureus
(MRSA), Streptococcus pneumoniae,
Enterococcus faecalis, and Bacillus
subtilis, and also is active against the
Gram-negative Haemophilus influenzae
(Phillips et al., 2011). It is the first potent
inhibitor of bacterial type-II topoiso-
merases discovered in the last 60 years,
and does not show cross-resistance with
other gyrase inhibitors. Its mechanism
of action is similar but not identical to
that of other gyrase inhibitors, such as
the coumarin antibiotics novobiocin and
coumermycin A1 and the fluoroquinoline
antibacterial ciprofloxacin. However,
kibdelomycin is active against novobio-Chemistry & Biology 18, August 26, 2011cin-resistant and coumermycin-resistant
strains ofS. aureus. It is also active against
the S. aureus strain that is resistant to
ciprofloxacin. The chemical genomics
profiling method used for the discovery
of kibdelomycin is based on the previously
developed S. aureus fitness test (SaFT)
(Donald et al., 2009; Huber et al., 2009)
and represents a highly powerful tool for
the discovery of new natural products
that is capable of predicting the mode of
action of the compound discovered.
The discovery of kibdelomycin gives
us hope that it will stimulate the industry
to return to the antibiotic area by use of
intelligent assay procedures that are ca-
pable of being used in a high-throughput
manner, thus facilitating the identification
of novel bioactive compounds.REFERENCES
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